<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063112</url>
  </required_header>
  <id_info>
    <org_study_id>Ethical committee 167</org_study_id>
    <nct_id>NCT03063112</nct_id>
  </id_info>
  <brief_title>Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain</brief_title>
  <acronym>RF</acronym>
  <official_title>Comparative Study Between Radiofrequency Thermocoagulation and Chemical Neurolysis of Thoracic Splanchnic Nerve Bilaterally for the Management of Abdominal Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares between the efficacy, safety and impact on the quality of life of
      radiofrequency thermocoagulation and chemical neurolysis of bilateral thoracic splanchnic
      nerves in the management of refractory pain which developed in patients suffering from upper
      abdominal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiofrequency thermocoagulation of splanchnic nerves was done bilaterally at level of
      thoracic vertebra T10 and T11 ( there were no enough studies done to test the efficacy,
      safety and impact on the quality of life of radiofrequency thermocoagulation of splanchnic
      nerves at level of T10 ). Aim of the Study is to compare between the efficacy, safety and
      impact on the quality of life of radiofrequency thermocoagulation of bilateral thoracic
      splanchnic nerves at level T10 and T11 vertebra and chemical neurolytic block of them at
      level of T11 vertebra only in the management of upper abdominal cancer pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">May 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>3 months</time_frame>
    <description>Visual analogue pain scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease the need for analgesic drugs</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of total oral morphine consumption dose in mg per day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Abdominal Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1( radiofrequency group )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 ( alcohol group )</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency generator device</intervention_name>
    <description>sympathetic blockade or ablation of thoracic splanchnic nerves</description>
    <arm_group_label>Group 1( radiofrequency group )</arm_group_label>
    <other_name>Physical neurolysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>sympathetic blockade or ablation of thoracic splanchnic nerves</description>
    <arm_group_label>Group 1( radiofrequency group )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>C arm fluoroscopic device</intervention_name>
    <description>sympathetic blockade or ablation of thoracic splanchnic nerves</description>
    <arm_group_label>Group 2 ( alcohol group )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyl alcohol</intervention_name>
    <description>sympathetic blockade or ablation of thoracic splanchnic nerves</description>
    <arm_group_label>Group 2 ( alcohol group )</arm_group_label>
    <other_name>Chemical neuolysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients suffering from upper abdominal cancer pain.

          2. Visceral pain with visual analogue pain score â‰¥ 4.

          3. Normal coagulation profile.

          4. Positive diagnostic test.

          5. Written informed consent from the patients .

        Exclusion Criteria:

          1. Patients with organ failure.

          2. Coagulation disorders.

          3. Local infection at the puncture site or sepsis.

          4. Allergy to the contrast dye or alcohol.

          5. Severe displacement of intra-abdominal structures.

          6. Pregnant women.

          7. Documented metastatic lesions.

          8. Psychiatric illness affecting cooperation.

          9. De-compensated cardiac disorders.

         10. Liver and renal dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samy A Erfan, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Head of the department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma Al Zahraa H Abdel Hameed, Lecturer</last_name>
    <phone>0201063684819</phone>
    <email>drfatmahamed15@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed H Othman, Professor</last_name>
    <phone>0201000525368</phone>
    <email>ahmadhothman@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South Egypt Cancer Institute</name>
      <address>
        <city>Assuit</city>
        <state>Assuit governrate</state>
        <zip>+20</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa M Esharkawy, Professor</last_name>
      <phone>0882332016</phone>
      <email>sru@seci.info</email>
    </contact>
    <contact_backup>
      <last_name>Doaa M Sayed, Professor</last_name>
      <phone>0882086671</phone>
      <email>seci99999@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>February 26, 2017</last_update_submitted>
  <last_update_submitted_qc>February 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Fatma Al Zahraa Hamed Abdel Hameed</investigator_full_name>
    <investigator_title>Lecturer of anasthesia and pain relief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Abdominal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

